Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EVANTHIA GALANIS

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1326028234
CMS profile
286517
Location
ROCHESTER, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$20,258.52

8 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $10,800.00 2
Travel and Lodging $9,305.36 3
Food and Beverage $153.16 3

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Boehringer Ingelheim International GmbH $18,258.52 7
Merck Sharp & Dohme LLC $2,000.00 1

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EVANTHIA GALANIS

NPI 1326028234 · CMS profile ID 286517

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

ROCHESTER, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1326028234?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EVANTHIA GALANIS, NPI 1326028234, CMS profile ID 286517. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1326028234?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). EVANTHIA GALANIS, NPI 1326028234, CMS profile ID 286517. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1326028234?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
EVANTHIA GALANIS, NPI 1326028234, CMS profile ID 286517, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1326028234?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

8 matching records · $20,258.52 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 8 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–8 of 8.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $2,000.0012/04/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141552268 CMS
Boehringer Ingelheim International GmbH $8,800.0004/04/2024 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1155218132 CMS
Boehringer Ingelheim International GmbH $371.7904/04/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155218134 CMS
Boehringer Ingelheim International GmbH $31.0802/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117963294 CMS
Boehringer Ingelheim International GmbH $51.1802/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117963296 CMS
Boehringer Ingelheim International GmbH $70.9002/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117963298 CMS
Boehringer Ingelheim International GmbH $376.0202/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117963300 CMS
Boehringer Ingelheim International GmbH $8,557.5502/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117963302 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $2,425.00 2
PY2024 $20,258.52 8

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $59,021,227.49 388
PY2024 Principal investigator $12,702,832.22 309
PY2023 Principal investigator $371,957.47 19
PY2022 Principal investigator $13,006.11 2
PY2021 Principal investigator $94,282.54 7
PY2020 Principal investigator $16,250.00 1
PY2019 Principal investigator $20,000.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

309 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Servier BioInnovation $1,350.00 12/23/2024 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1153019263
Principal investigator 1 Servier BioInnovation $450.00 12/23/2024 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1153019265
Principal investigator 1 PFIZER INC. $69,595.00 12/16/2024 Non-covered Recipient Entity
ALLIANCE FOR CLINICAL TRIALS
A042001 A RANDOMIZED PHASE II STUDY COMPARING INOTUZUMAB PLUS CHEMOTHERAPY VERSUS STANDARD CHEMOTHERAPY IN OLDER ADULTS WITH PHILADELPHIACHROMOSOMENEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA WI261343 No dispute reported 06/30/2026 1130946225
Principal investigator 1 Servier BioInnovation $21,934.44 12/16/2024 Covered Recipient Teaching Hospital
Mayo Clinic Hospital Rochester
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1153015127
Principal investigator 1 Servier BioInnovation $21,934.44 12/16/2024 Covered Recipient Teaching Hospital
Mayo Clinic Hospital Rochester
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1153015129
Principal investigator 1 PFIZER INC. $208,785.00 12/11/2024 Non-covered Recipient Entity
ALLIANCE FOR CLINICAL TRIALS
A042001 A RANDOMIZED PHASE II STUDY COMPARING INOTUZUMAB PLUS CHEMOTHERAPY VERSUS STANDARD CHEMOTHERAPY IN OLDER ADULTS WITH PHILADELPHIACHROMOSOMENEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA WI261343 No dispute reported 06/30/2026 1130946231
Principal investigator 1 PFIZER INC. $50,944.32 12/09/2024 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
A PHASE III RANDOMIZED OPEN LABEL TRAILO TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB ANTIHER2 THERAPY ENDOCRINE THERAPY VS ANTIHER2 THERAPY ENDOCRINE THERAPY AFTER INDUCTION TREATMENT FOR HORMONE RECEPTION POSITIVE HRHER2 POSITIVE METASTATIC BREAST CANCER MBC1 No dispute reported 06/30/2026 1130916217
Principal investigator 1 PFIZER INC. $161,993.33 12/09/2024 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1130944790
Principal investigator 1 PFIZER INC. $1,360,744.00 12/09/2024 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1130946338
Principal investigator 1 Servier BioInnovation $21,934.44 11/19/2024 Covered Recipient Teaching Hospital
Mayo Clinic Hospital Rochester
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1153015123
Principal investigator 1 Servier BioInnovation $21,934.44 11/19/2024 Covered Recipient Teaching Hospital
Mayo Clinic Hospital Rochester
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1153015125
Principal investigator 1 PFIZER INC. $73,457.85 11/12/2024 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
A PHASE III RANDOMIZED OPEN LABEL TRAILO TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB ANTIHER2 THERAPY ENDOCRINE THERAPY VS ANTIHER2 THERAPY ENDOCRINE THERAPY AFTER INDUCTION TREATMENT FOR HORMONE RECEPTION POSITIVE HRHER2 POSITIVE METASTATIC BREAST CANCER MBC1 No dispute reported 06/30/2026 1130916092
Principal investigator 1 PFIZER INC. $161,993.33 11/12/2024 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1130944784
Principal investigator 1 Genentech, Inc. $8,535.00 10/29/2024 Non-covered Recipient Entity
ALLIANCE FNDN TRIALS LLC ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY FNDN
AFT57 Induction and adjuvant atezolizumab with or without tiragolumab in stage III NSCLC Randomize No dispute reported 06/30/2026 1133379390
Principal investigator 1 Servier BioInnovation $21,934.44 10/21/2024 Covered Recipient Teaching Hospital
Mayo Clinic Hospital Rochester
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1153015119
Principal investigator 1 Servier BioInnovation $21,934.44 10/21/2024 Covered Recipient Teaching Hospital
Mayo Clinic Hospital Rochester
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1153015121
Principal investigator 1 PFIZER INC. $50,944.32 10/15/2024 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
A PHASE III RANDOMIZED OPEN LABEL TRAILO TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB ANTIHER2 THERAPY ENDOCRINE THERAPY VS ANTIHER2 THERAPY ENDOCRINE THERAPY AFTER INDUCTION TREATMENT FOR HORMONE RECEPTION POSITIVE HRHER2 POSITIVE METASTATIC BREAST CANCER MBC1 No dispute reported 06/30/2026 1130916089
Principal investigator 1 PFIZER INC. $161,993.33 10/07/2024 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1130944778
Principal investigator 1 PFIZER INC. $60,455.79 09/30/2024 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
A PHASE III RANDOMIZED OPEN LABEL TRAILO TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB ANTIHER2 THERAPY ENDOCRINE THERAPY VS ANTIHER2 THERAPY ENDOCRINE THERAPY AFTER INDUCTION TREATMENT FOR HORMONE RECEPTION POSITIVE HRHER2 POSITIVE METASTATIC BREAST CANCER MBC1 No dispute reported 06/30/2026 1155254004
Principal investigator 1 PFIZER INC. $183,902.50 09/30/2024 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
A PHASE III RANDOMIZED OPEN LABEL TRAILO TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB ANTIHER2 THERAPY ENDOCRINE THERAPY VS ANTIHER2 THERAPY ENDOCRINE THERAPY AFTER INDUCTION TREATMENT FOR HORMONE RECEPTION POSITIVE HRHER2 POSITIVE METASTATIC BREAST CANCER MBC1 No dispute reported 06/30/2026 1155254008
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $44,221.80 09/27/2024 Non-covered Recipient Entity
Alliance For Clinical Trials In Oncology Foundation
A062101 A phase I/II study of the safety, tolerability and efficacy of Belantamab mafodotin (GSK2857916) in combination with Iberdomide (CC-220) / dexamethasone versus Belantamab mafodotin (GSK2857916)/dexamethasone in RRMM No dispute reported 06/30/2026 1123475810
Principal investigator 1 PFIZER INC. $125,271.00 09/26/2024 Non-covered Recipient Entity
ALLIANCE FOR CLINICAL TRIALS
A042001 A RANDOMIZED PHASE II STUDY COMPARING INOTUZUMAB PLUS CHEMOTHERAPY VERSUS STANDARD CHEMOTHERAPY IN OLDER ADULTS WITH PHILADELPHIACHROMOSOMENEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA WI261343 No dispute reported 06/30/2026 1130990558
Principal investigator 1 Servier BioInnovation $21,934.44 09/19/2024 Covered Recipient Teaching Hospital
Mayo Clinic Hospital Rochester
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1153015115
Principal investigator 1 Servier BioInnovation $21,934.44 09/19/2024 Covered Recipient Teaching Hospital
Mayo Clinic Hospital Rochester
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1153015117
Principal investigator 1 PFIZER INC. $50,944.32 09/09/2024 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
A PHASE III RANDOMIZED OPEN LABEL TRAILO TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB ANTIHER2 THERAPY ENDOCRINE THERAPY VS ANTIHER2 THERAPY ENDOCRINE THERAPY AFTER INDUCTION TREATMENT FOR HORMONE RECEPTION POSITIVE HRHER2 POSITIVE METASTATIC BREAST CANCER MBC1 No dispute reported 06/30/2026 1155254006
Principal investigator 1 PFIZER INC. $902,760.80 08/29/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology and Mayo Clinic Rochester
A042001 A RANDOMIZED PHASE II STUDY COMPARING INOTUZUMAB PLUS CHEMOTHERAPY VERSUS STANDARD CHEMOTHERAPY IN OLDER ADULTS WITH PHILADELPHIACHROMOSOMENEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA WI261343 No dispute reported 06/30/2026 1130900163
Principal investigator 1 PFIZER INC. $902,760.80 08/29/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology and Mayo Clinic Rochester
A042001 A RANDOMIZED PHASE II STUDY COMPARING INOTUZUMAB PLUS CHEMOTHERAPY VERSUS STANDARD CHEMOTHERAPY IN OLDER ADULTS WITH PHILADELPHIACHROMOSOMENEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA WI261343 No dispute reported 06/30/2026 1130900253
Principal investigator 1 Genentech, Inc. $617,264.48 08/28/2024 Non-covered Recipient Entity
ALLIANCE FNDN TRIALS LLC ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY FNDN
A PHASE IB II UMBRELLA STUDY OF TARGETED AGENTS WITH ATEZOLIZUMAB FOR PATIENTS WITH RECURRENT OR PER No dispute reported 06/30/2026 1133379386
Principal investigator 1 Servier BioInnovation $21,934.44 08/26/2024 Covered Recipient Teaching Hospital
Mayo Clinic Hospital Rochester
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1153015111
Principal investigator 1 Servier BioInnovation $21,934.44 08/26/2024 Covered Recipient Teaching Hospital
Mayo Clinic Hospital Rochester
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1153015113
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626588
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626590
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626592
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626594
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626596
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626598
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626600
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626602
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626604
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626606
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626608
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626610
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626612
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626614
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626616
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626618
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626620
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626622
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626624
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626626
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626628
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626630
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626632
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626634
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626636
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626638
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626641
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626643
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626645
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626647
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626649
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626651
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626653
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626655
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626657
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626659
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626661
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626663
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626665
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626667
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626669
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626671
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626673
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626675
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626677
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626679
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626681
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626683
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626685
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626687
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626689
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626691
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626693
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626695
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626697
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626699
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626701
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626703
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626705
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626707
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626709
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626711
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626713
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626715
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626717
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626719
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626721
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626723
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626725
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626727
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626729
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626731
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626733
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626735
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626737
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626739
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626741
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626743
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626745
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626747
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626749
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626751
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626753
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626755
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626757
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626759
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626761
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626763
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626765
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626767
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626769
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626771
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626773
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626775
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626777
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626779
Principal investigator 1 Exelixis Inc. $108.00 08/15/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study No dispute reported 06/30/2026 1138626781
Principal investigator 1 Servier BioInnovation $1,579.00 08/14/2024 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1153019271
Principal investigator 1 Servier BioInnovation $2,003.00 08/14/2024 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1153019273
Principal investigator 1 PFIZER INC. $161,993.33 08/01/2024 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1131034569
Principal investigator 1 PFIZER INC. $50,944.32 07/30/2024 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
A PHASE III RANDOMIZED OPEN LABEL TRAILO TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB ANTIHER2 THERAPY ENDOCRINE THERAPY VS ANTIHER2 THERAPY ENDOCRINE THERAPY AFTER INDUCTION TREATMENT FOR HORMONE RECEPTION POSITIVE HRHER2 POSITIVE METASTATIC BREAST CANCER MBC1 No dispute reported 06/30/2026 1130916221
Principal investigator 1 PFIZER INC. $50,944.32 07/15/2024 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
A PHASE III RANDOMIZED OPEN LABEL TRAILO TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB ANTIHER2 THERAPY ENDOCRINE THERAPY VS ANTIHER2 THERAPY ENDOCRINE THERAPY AFTER INDUCTION TREATMENT FOR HORMONE RECEPTION POSITIVE HRHER2 POSITIVE METASTATIC BREAST CANCER MBC1 No dispute reported 06/30/2026 1130916225
Principal investigator 1 PFIZER INC. $161,993.33 07/08/2024 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1131034617
Principal investigator 1 PFIZER INC. $564,225.50 06/25/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology and Mayo Clinic Rochester
A042001 A RANDOMIZED PHASE II STUDY COMPARING INOTUZUMAB PLUS CHEMOTHERAPY VERSUS STANDARD CHEMOTHERAPY IN OLDER ADULTS WITH PHILADELPHIACHROMOSOMENEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA WI261343 No dispute reported 06/30/2026 1130899831
Principal investigator 1 PFIZER INC. $564,225.50 06/25/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology and Mayo Clinic Rochester
A042001 A RANDOMIZED PHASE II STUDY COMPARING INOTUZUMAB PLUS CHEMOTHERAPY VERSUS STANDARD CHEMOTHERAPY IN OLDER ADULTS WITH PHILADELPHIACHROMOSOMENEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA WI261343 No dispute reported 06/30/2026 1130900167
Principal investigator 1 Servier BioInnovation $1,579.00 06/24/2024 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation No dispute reported 06/30/2026 1153019315
Principal investigator 1 Servier BioInnovation $2,003.00 06/24/2024 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation No dispute reported 06/30/2026 1153019323
Principal investigator 1 PFIZER INC. $167,028.00 06/14/2024 Non-covered Recipient Entity
ALLIANCE FOR CLINICAL TRIALS
A042001 A RANDOMIZED PHASE II STUDY COMPARING INOTUZUMAB PLUS CHEMOTHERAPY VERSUS STANDARD CHEMOTHERAPY IN OLDER ADULTS WITH PHILADELPHIACHROMOSOMENEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA WI261343 No dispute reported 06/30/2026 1131040394
Principal investigator 1 PFIZER INC. $156,757.14 06/11/2024 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCE No dispute reported 06/30/2026 1131040174
Principal investigator 1 PFIZER INC. $50,944.32 06/11/2024 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
A PHASE III RANDOMIZED OPEN LABEL TRAILO TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB ANTIHER2 THERAPY ENDOCRINE THERAPY VS ANTIHER2 THERAPY ENDOCRINE THERAPY AFTER INDUCTION TREATMENT FOR HORMONE RECEPTION POSITIVE HRHER2 POSITIVE METASTATIC BREAST CANCER MBC1 No dispute reported 06/30/2026 1155254022
Principal investigator 1 PFIZER INC. $161,993.33 05/13/2024 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCE No dispute reported 06/30/2026 1131040099
Principal investigator 1 Servier BioInnovation $5,500.00 05/03/2024 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation No dispute reported 06/30/2026 1153019313
Principal investigator 1 Servier BioInnovation $1,250.00 05/03/2024 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation No dispute reported 06/30/2026 1153019325
Principal investigator 1 Servier BioInnovation $1,500.00 05/03/2024 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation No dispute reported 06/30/2026 1153019327
Principal investigator 1 PFIZER INC. $156,757.14 04/22/2024 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCE No dispute reported 06/30/2026 1131067830
Principal investigator 1 PFIZER INC. $238,618.50 04/18/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology and Mayo Clinic Rochester
RANDOMIZED TRIAL OF CONSOLIDATION TARGETED ADJUVANT THERAPY WITH ENCORAFENIB AND CETUXIMAB VERSUS USUAL CARE FOR PATIENTS WITH STAGE II AND III BRAF V600E COLON CANCERWI261502 No dispute reported 06/30/2026 1131011609
Principal investigator 1 Servier BioInnovation $1,579.00 04/08/2024 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation No dispute reported 06/30/2026 1153019305
Principal investigator 1 Servier BioInnovation $2,250.00 04/05/2024 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation No dispute reported 06/30/2026 1153019317
Principal investigator 1 Servier BioInnovation $100.00 04/05/2024 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation No dispute reported 06/30/2026 1153019319
Principal investigator 1 PFIZER INC. $1,938,294.00 03/18/2024 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCE No dispute reported 06/30/2026 1131078319
Principal investigator 1 PFIZER INC. $161,993.33 03/18/2024 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCE No dispute reported 06/30/2026 1131078326
Principal investigator 1 PFIZER INC. $41,432.85 03/11/2024 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
PATINAA RANDOMIZED OPEN LABEL PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB ANTIHER2 THERAPY ENDOCRINE THERAPY VS ANTIHER2 THERAPY ENDOCRINE THERAPY AFTER INDUCTION TREATMENT FOR HRHER2 METASTATIC BREAST CANCER No dispute reported 06/30/2026 1131074928
Principal investigator 1 Servier BioInnovation $1,579.00 03/11/2024 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation No dispute reported 06/30/2026 1153019269
Principal investigator 1 PFIZER INC. $564,225.50 02/20/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology and Mayo Clinic Rochester
A042001 A RANDOMIZED PHASE II STUDY COMPARING INOTUZUMAB PLUS CHEMOTHERAPY VERSUS STANDARD CHEMOTHERAPY IN OLDER ADULTS WITH PHILADELPHIACHROMOSOMENEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA WI261343 No dispute reported 06/30/2026 1130900249
Principal investigator 1 PFIZER INC. $564,225.50 02/20/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology and Mayo Clinic Rochester
A042001 A RANDOMIZED PHASE II STUDY COMPARING INOTUZUMAB PLUS CHEMOTHERAPY VERSUS STANDARD CHEMOTHERAPY IN OLDER ADULTS WITH PHILADELPHIACHROMOSOMENEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA WI261343 No dispute reported 06/30/2026 1130900257
Principal investigator 1 Exelixis Inc. $122.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626296
Principal investigator 1 Exelixis Inc. $122.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626298
Principal investigator 1 Exelixis Inc. $122.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626300
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626302
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626304
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626306
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626308
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626310
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626312
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626314
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626316
Principal investigator 1 Exelixis Inc. $122.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626318
Principal investigator 1 Exelixis Inc. $3,000.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626320
Principal investigator 1 Exelixis Inc. $4,500.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626322
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626324
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626326
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626328
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626330
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626332
Principal investigator 1 Exelixis Inc. $122.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626334
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626336
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626338
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626340
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626342
Principal investigator 1 Exelixis Inc. $4,500.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626344
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626346
Principal investigator 1 Exelixis Inc. $122.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626348
Principal investigator 1 Exelixis Inc. $122.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626350
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626352
Principal investigator 1 Exelixis Inc. $122.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626354
Principal investigator 1 Exelixis Inc. $25.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626356
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626358
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626360
Principal investigator 1 Exelixis Inc. $4,500.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626362
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626364
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626366
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626368
Principal investigator 1 Exelixis Inc. $122.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626370
Principal investigator 1 Exelixis Inc. $122.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626372
Principal investigator 1 Exelixis Inc. $122.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626374
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626376
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626378
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626380
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626382
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626384
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626386
Principal investigator 1 Exelixis Inc. $25.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626388
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626390
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626392
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626394
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626396
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626398
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626400
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626402
Principal investigator 1 Exelixis Inc. $122.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626404
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626406
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626408
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626410
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626412
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626414
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626416
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626418
Principal investigator 1 Exelixis Inc. $25.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626420
Principal investigator 1 Exelixis Inc. $122.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626422
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626424
Principal investigator 1 Exelixis Inc. $25.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626426
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626428
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626430
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626432
Principal investigator 1 Exelixis Inc. $4,500.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626434
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626436
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626438
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626440
Principal investigator 1 Exelixis Inc. $122.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626442
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626444
Principal investigator 1 Exelixis Inc. $4,500.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626446
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626448
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626450
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626452
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626454
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626456
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626458
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626460
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626462
Principal investigator 1 Exelixis Inc. $122.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626464
Principal investigator 1 Exelixis Inc. $25.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626466
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626468
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626470
Principal investigator 1 Exelixis Inc. $4,500.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626472
Principal investigator 1 Exelixis Inc. $3,000.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626474
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626476
Principal investigator 1 Exelixis Inc. $25.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626478
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626480
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626482
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626484
Principal investigator 1 Exelixis Inc. $122.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626486
Principal investigator 1 Exelixis Inc. $122.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626488
Principal investigator 1 Exelixis Inc. $122.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626490
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626492
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626494
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626496
Principal investigator 1 Exelixis Inc. $122.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626498
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626500
Principal investigator 1 Exelixis Inc. $122.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626502
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626504
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626506
Principal investigator 1 Exelixis Inc. $122.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626508
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626510
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626512
Principal investigator 1 Exelixis Inc. $122.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626514
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626516
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626518
Principal investigator 1 Exelixis Inc. $122.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626520
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626522
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626524
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626526
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626528
Principal investigator 1 Exelixis Inc. $122.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626530
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626532
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626534
Principal investigator 1 Exelixis Inc. $122.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626536
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626538
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626540
Principal investigator 1 Exelixis Inc. $122.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626542
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626544
Principal investigator 1 Exelixis Inc. $122.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626546
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626548
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626550
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626552
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626554
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626556
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626558
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626560
Principal investigator 1 Exelixis Inc. $122.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626562
Principal investigator 1 Exelixis Inc. $122.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626564
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626566
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626568
Principal investigator 1 Exelixis Inc. $25.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626570
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626572
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626574
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626576
Principal investigator 1 Exelixis Inc. $122.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626578
Principal investigator 1 Exelixis Inc. $122.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626580
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626582
Principal investigator 1 Exelixis Inc. $122.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626584
Principal investigator 1 Exelixis Inc. $108.00 02/08/2024 Non-covered Recipient Entity
Alliance for Clinical Trials in Oncology Foundation
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET) No dispute reported 06/30/2026 1138626586
Principal investigator 1 PFIZER INC. $318,750.47 01/22/2024 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1131084856
Principal investigator 1 Servier BioInnovation $2,003.00 01/10/2024 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation No dispute reported 06/30/2026 1153019283
Principal investigator 1 Servier BioInnovation $900.00 01/10/2024 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation No dispute reported 06/30/2026 1153019285
Principal investigator 1 Servier BioInnovation $350.00 01/10/2024 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation No dispute reported 06/30/2026 1153019287
Principal investigator 1 Servier BioInnovation $1,579.00 01/10/2024 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation No dispute reported 06/30/2026 1153019295
Principal investigator 1 Servier BioInnovation $1,579.00 01/10/2024 Non-covered Recipient Entity
MAYO CLINIC JACKSONVILLE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation No dispute reported 06/30/2026 1153019297
Principal investigator 1 AstraZeneca Pharmaceuticals LP $805,444.00 01/09/2024 Non-covered Recipient Entity
ALLIANCE FOR CLINICAL TRIALS
CHIO3 Trial Chemotherapy Combined with Immune Checkpoint Inhibitor for Operable stage IIIA Non Small Cell Lung Cancer No dispute reported 06/30/2026 1110844302
Principal investigator 1 PFIZER INC. $318,750.47 01/02/2024 Non-covered Recipient Entity
ALLIANCE FOUNDATION TRIALS LLC
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1131084424